German cross-country skier and Olympic champion Victoria Carl fails doping test
The 29-year-old Carl, who won gold in the cross-country team sprint alongside Katharina Henning at the 2022 Beijing Olympics, failed the test after her final race at the Military World Games in March. She also finished second in the overall World Cup standings last season.
The skiing association, known by its German acronym DSV, said Carl's positive test for clenbuterol arose after she was given the wrong cough syrup to treat acute spastic bronchitis by a German army doctor.
'This is a regrettable isolated incident that arose from an unfortunate combination of organizational and medical circumstances – not from any intent to deceive the athlete,' the DSV said.
The DSV published a statement from the German army's medical service saying the skier was erroneously given the combination drug Spasmo Mucosolvan containing ambroxol and clenbuterol instead of Mucosolvan containing just ambroxol.
Germany's National Anti-Doping Agency has initiated proceedings. The DSV and German army said they're hoping for the athlete's 'complete acquittal.'
The 2026 Milan-Cortina Winter Games open on Feb. 6.
___
AP skiing: https://apnews.com/hub/alpine/skiing
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New York Times
31 minutes ago
- New York Times
Deossa and Arias
Serhou Guirassy's first-half brace was enough to send his side through to an all-European quarter-final Getty Images Stats Perform / Getty Images Two minutes of first-half stoppage time pass without much incident. Dortmund hit the break leading by two goals thanks to Serhou Guirassy's brace. Getty Images On the occasions that Monterrey do get forward and create some good opportunities, they just don't have enough bodies forward to provide a credible threat. There are too many yellow shirts in the way and the promising attacks have tended to fizzle out. 44' Borussia Dortmund 2-0 Monterrey Corona leads a swift counter-attack from the halfway line. He won't win the footrace to goal so he checks back, only managing to win a corner in the end which Dortmund deal with comfortably. 41' Borussia Dortmund 2-0 Monterrey Corona breaks free down the left wing and makes a lovely move to skip past his nearest defender. He advances into the box and looks to beat Kobel from point-blank range, but the goalkeeper makes the stop. Corona had an opportunity to go down in the box under contact, which may have won him a penalty, but he stayed on his feet instead. Getty Images Former La Liga wonder kid Oliver Torres has found a home in Monterrey. Tonight, however, he has been unimpressive in central midfield. Hurried and anxious on the ball, the 30-year-old baby-faced Spaniard has underwhelmed. Nelson Deossa, on the other hand, has had a wonderful tournament. The left-footed Colombian playmaker has put himself in the European shop window during this competition. Not the 2013 Champions League semi-final, Mario? Too soon? Getty Images When all the media were preparing their stories about the Bellingham brothers facing off in case there was a Madrid-Dortmund match-up in the quarter-final, Jobe's unexpected absence could lead to more talk about, mmm, the Champions League 2024 final maybe? 31' Borussia Dortmund 2-0 Monterrey Bellingham sets up Guirassy in front of goal, but as he slides Guirassy is just barely unable to make strong-enough contact to direct the ball into the open corner of the net. That would have been a first-half hat-trick. Getty Images For those who needed a reminder of just how clinical of a goalscorer Serhou Guirassy is, his rate of 0.73 league goals per 90 minutes this past season were better than Manchester City's Erling Haaland, Barcelona's Raphinha and…Nottingham Forest's Chris Wood. 28' Borussia Dortmund 2-0 Monterrey Bellingham scythes down Deossa near the corner flag and is shown a deserved yellow card. That means, if Dortmund advance here, he's suspended for the quarter-final meeting with his brother, Jude, and Real Madrid! Getty Images Monterrey had reacted well but, and forgive the typical phrase, at the highest level mistakes are very damaging. The Mexicans failed in the opponent's area and were weak defending, once again unable to stop the Adeyemi-Guirassy duo. Karim Adeyemi's pace has been on full display so far in Atlanta. What a player he is. Monterrey's defenders are on their heels anytime the German attacker is on the ball. 2-0 for Dortmund and they can smell blood just 27 minutes into this match. It's exactly the same link-up — Adeyemi and Guirassy — to put Dortmund 2-0 up. Whereas the first goal was all about clever play in tight spaces, this one showcased the speed of Adeyemi, stretching the Monterrey defence on the right and then taking his time to play a perfectly weighted pass into the path of Guirassy, who again finished superbly. Getty Images 24' Borussia Dortmund 2-0 Monterrey Adeyemi breaks free down the right wing and draws the attention of two defenders before rolling the box into the centre for Guirassy, who finishes at the near post again! Getty Images Guirassy's strike was a beautifully taken goal that underlined what an excellent centre-forward he has become. A shame for Monterrey that Corona couldn't show quite the same composure at the other end a few minutes later, going fractionally too early with his run, getting flagged offside, and unable to find a way past Kobel anyway. Going back to Dortmund's goal, it was a smart move by Adeyemi to find that space inside, Rodriguez has been unable to read the play and Guirassy was in a very good position to score. That's the earliest goal Dortmund have scored in this tournament, but it doesn't look like Monterrey will give up so soon. 19' Borussia Dortmund 1-0 Monterrey Corona breaks free on goal but can't manage to beat Kobel one-on-one. The offside flag goes up immediately afterward to spare his blushes. Ryerson had done well to step up and put Corona offside. Getty Images Argentine referee Facundo Tello is well-respected in CONMEBOL circles and globally, as well. Facundo refereed three matches at the 2022 World Cup in Qatar. He also featured at Euro 2024 as the the first non-UEFA official to referee a match at a major European tournament.
Yahoo
an hour ago
- Yahoo
Bayern consider Rashford move - Wednesday's gossip
Bayern Munich consider move for Marcus Rashford, Arsenal close in on deal for Viktor Gyokeres, Crystal Palace agree £47m price for Ousmane Diomande. Bayern Munich are considering a shock move for Manchester United and England forward Marcus Rashford, 27, after being impressed by his form on loan at Aston Villa last season. (Sun) Advertisement Arsenal are moving closer to a deal for Sporting forward Viktor Gyokeres. The 27-year-old Swede has told his club he wants to join the Gunners. (L'Equipe - in French) Crystal Palace have reached a £47m agreement to sign Ousmane Diomande, 21, from Sporting with the Ivory Coast defender seen as a potential replacement for 24-year-old England international Marc Guehi. (A Bola - in Portuguese) Manchester United have approached Inter Milan about a deal to sign Italy midfielder Davide Frattesi, 25. (Caught Offside) Arsenal have already submitted an offer to England winger Noni Madueke, 23, who might leave Chelsea in the summer. (Sky Germany) Advertisement Juventus are closing in on a deal to sign Canada forward Jonathan David, 25, whose contract expired at Lille at the end of last season. (Fabrizio Romano) Colombia forward Jhon Duran, 22, is flying from his homeland to Turkey to complete a loan move from Al-Nassr to Fenerbahce. (Athletic - subscription required) Newcastle are exploring a move for Marseille and Argentina centre-back Leonardo Balerdi, 26, who is also interesting Juventus. (Mail - subscription required) Burnley are working on striker options for manager Scott Parker with Genk and Nigeria forward Tolu Arokodare, 24, under consideration. (Telegraph - subscription required) Advertisement AC Milan are hoping to sign Switzerland midfielder Ardon Jashari, 22, from Club Brugge in a deal worth about £30m. (La Gazzetta dello Sport - in Italian) Manchester City will sign 15-year-old Caelan-Kole Cadamarteri from Sheffield Wednesday in a £1.5m deal. The forward is the son of former Everton striker Danny. (Mail) West Ham face a battle to convince Slavia Prague to sell Senegal left-back El Hadji Malick Diouf, 20. (Guardian)
Yahoo
an hour ago
- Yahoo
Ozempic Alternative Ditches The Needle And One Major Side Effect
A drug that can be taken orally could soon rival the likes of Ozempic for treating type 2 diabetes and obesity, according to a new study. Although its efficacy hasn't yet been tested in humans, the compound could bypass some of the harmful side-effects associated with similar drugs. Unlike the famous family of GLP-1 receptor agonist drugs, this new candidate targets the β2-adrenergic receptor (β2AR). Drugs that do this aren't new: salbutamol (sold as Ventolin among other brand names) is widely prescribed for use in short stints to treat asthma and chronic obstructive pulmonary disease. Clenbuterol is also prescribed for asthma in some countries, though it's better known as a performance-enhancing drug, banned by the World Anti-Doping Agency for its anabolic effects. For more than a decade, scientists have been trying to find a way to harness the benefits of β2AR agonists, without setting off their harmful effects. They can stimulate skeletal muscle glucose uptake and burn fat, mimicking the effects of exercise – but they have been considered too risky for treating diabetes or obesity, because of their tendency to wreak havoc on the heart. Related: The body's β2-adrenergic receptors are coupled with G proteins, and when activated for long periods (by β2AR drugs, for instance), the G proteins set off a chain reaction which leads to cardiovascular problems. "That would lead to heart rate increases, systolic blood pressure increases, and, eventually, that over-sustained exposure would lead to increases in heart weight and cardiac hypertrophy," molecular biologist Shane Wright, from Karolinska Institute in Sweden, told Mar de Miguel of Bioworld. But a campaign led by scientists from the Karolinska Institute, Stockholm University, and the biotech company Atrogi AB has revealed a series of β2AR agonist molecules that can side-step the slippery slope triggered by the G proteins. By activating only specific pathways, one of these – dubbed 'compound 15' – seems less likely to cause those concerning side effects, though we won't know for sure until further clinical trials are carried out. Unlike GLP-1 receptor agonists like Ozempic, compound 15 doesn't suppress appetite or lead to muscle loss, which means it may be safer in that regard too. It's also much more user-friendly, as a drug that can be swallowed rather than injected. "The goal was to try to target this other action that this receptor has expressed in the skeletal muscle, not in the heart, where it is mediating glucose uptake as a very beneficial outlet for lowering blood glucose levels," Wright said. So far, the newly-designed drug has been tested in lab-grown cells, male mice, rats, beagles, and phase 1 clinical trials (which only test for safety, not efficacy) in healthy and type 2 diabetic men. "Lead candidates of the chemical series increased glucose tolerance in preclinical models of diabetes and obesity with little or no increase in contractile force, cardiac lesions, and cardiac hypertrophy," the authors report. They also reversed muscle atrophy induced by GLP-1 drugs. "Clinical evaluation demonstrated that our lead candidate was orally bioavailable and safe in both healthy volunteers and type 2 diabetics, underlining its therapeutic potential." Many more tests – and a catchier name – will be needed before compound 15 or its relatives are made available as an alternative to GLP-1 drugs. Phase 2 clinical trials are underway to see if the enhanced muscle growth, balanced glucose levels, and insulin sensitivity seen in animal tests hold up in human bodies. "A well-tolerated GRK2-biased agonist offers significant therapeutic potential beyond type 2 diabetes and obesity… like muscular dystrophy and sarcopenia," the authors add. The research was published in Cell. A Simple Change To Your Evening Routine Could Help You Exercise More 'Sky-High' Levels of Alzheimer's Protein Found in Newborns Alzheimer's Might Not Actually Be a Brain Disease, Says Expert
